Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

255

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

November 30, 2005

Study Completion Date

October 31, 2006

Conditions

Breast CancerMetastasesBone Metastases in Subjects With Advanced Breast Cancer

Interventions

BIOLOGICAL

Denosumab

Denosumab administered by subcutaneous injection

DRUG

IV Bisphosphonates

Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid